General American Investors Co. Inc. Purchases 140,000 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

General American Investors Co. Inc. lifted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 116.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 260,261 shares of the company's stock after purchasing an additional 140,000 shares during the period. General American Investors Co. Inc. owned about 0.30% of IDEAYA Biosciences worth $4,263,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in IDEAYA Biosciences in the 4th quarter worth about $47,000. CWM LLC increased its holdings in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after acquiring an additional 1,814 shares during the last quarter. Signaturefd LLC increased its holdings in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after acquiring an additional 2,271 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in IDEAYA Biosciences by 46.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after acquiring an additional 2,112 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in IDEAYA Biosciences by 2,490.9% in the 1st quarter. GAMMA Investing LLC now owns 7,125 shares of the company's stock worth $1,170,000 after acquiring an additional 6,850 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Trading Down 2.3%

Shares of NASDAQ IDYA traded down $0.50 during midday trading on Friday, hitting $21.59. 549,679 shares of the company's stock were exchanged, compared to its average volume of 989,677. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -6.01 and a beta of 0.03. The business's fifty day moving average price is $20.91 and its two-hundred day moving average price is $20.36.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) earnings per share. Equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective for the company. Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price objective for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a report on Thursday, July 10th. Finally, JPMorgan Chase & Co. lifted their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a report on Thursday, May 22nd. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $47.55.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.